Author

M. McCavitt-Malvido

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:mouse· 2 Assay:metagenomics· 1 Organism:non-human primate· 1

Frequent Co-Authors

I. P. Chen· 2 shared M. Ott· 2 shared A. Ashworth· 1 shared A. Marimuthu· 1 shared B. Sreekumar· 1 shared C. Ha· 1 shared C. J. Roy· 1 shared C. L. Moyer· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

I. P. Chen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologymBioPeer-reviewedJun 9, 2023

Mild SARS-CoV-2 infection results in long-lasting microbiota instability

V. Upadhyay, R. Suryawanshi, P. Tasoff…·P. J. Turnbaugh

This study shows that mild SARS-CoV-2 infection causes long-term gut microbiota instability in both humans and mice, with Omicron variant also disrupting microbial communities despite causing milder symptoms.

DOI 10.1128/mbio.00889-23

humanmouse

𝕏 PostBluesky

MicrobiologybioRxivPreprintApr 18, 2023

A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis in vivo

T. Y. Taha, R. K. Suryawanshi, I. P. Chen…·M. Ott

This study shows that mutating the SARS-CoV-2 NSP3 Mac1 domain reduces viral replication and pathogenesis in vivo.

DOI 10.1101/2023.04.18.537104

humanmouse

𝕏 PostBluesky

MicrobiologybioRxivJan 6, 2022

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a pan-Ebolavirus Immunotherapeutic

E. Kuang, R. W. Cross, M. McCavitt-Malvido…·Z. A. Bornholdt

This study shows that a single intramuscular dose of MBP431, a modified ebolavirus therapeutic, can reverse disease and provide protection in non-human primates.

DOI 10.3390/pathogens11060655

non-human primateexperimental assay

𝕏 PostBluesky